Related Experiment Videos
Richter's transformation in chronic lymphocytic leukemia
Apostolia-Maria Tsimberidou1, Michael J Keating
1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. atsimber@mdanderson.org
Seminars in Oncology
|April 18, 2006
Summary
Richter's syndrome (RS), a transformation of chronic lymphocytic leukemia (CLL) into lymphoma, has a 3.9% incidence. Novel therapies combining chemotherapy, immunotherapy, and stem cell transplant show promise for treating this aggressive condition.
Area of Science:
- Hematology
- Oncology
- Cancer Biology
Background:
- Richter's syndrome (RS) is a transformation of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma into high-grade non-Hodgkin's lymphoma (NHL).
- The incidence of RS at our institution is 3.9%, with transformations potentially arising from the original CLL clone or as a new neoplasm.
- Viral infections like Epstein-Barr virus (EBV) and genetic abnormalities including trisomy 12 and chromosome 11 may trigger CLL transformation into RS.
Purpose of the Study:
- To investigate the incidence, characteristics, and therapeutic outcomes of Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL).
- To evaluate the efficacy of current and novel therapeutic strategies for RS, including chemotherapy, immunotherapy, and allogeneic stem cell transplantation.
- To report on the median survival and failure-free survival durations for patients with RS treated at our institution.
Main Methods:
- Retrospective analysis of patients diagnosed with Richter's syndrome (RS) at The University of Texas M.D. Anderson Cancer Center.
- Review of therapeutic strategies, including chemotherapy, immunotherapy, and allogeneic stem cell transplantation, for RS.
- Analysis of clinical trial data for a novel combination therapy involving oxaliplatin, fludarabine, cytarabine, and rituximab, followed by postremission therapy.
Main Results:
- The median overall survival for patients with RS at our institution is 9.1 months, with a median failure-free survival of 7.1 months.
- Conventional therapies for RS, typically used for NHL or acute lymphoblastic leukemia, show response rates ranging from 5% to 43%.
- Patients receiving cytoreductive therapy with chemotherapy and immunotherapy, followed by allogeneic stem cell transplantation, appear to benefit.
Conclusions:
- Richter's syndrome (RS) represents an aggressive transformation of CLL requiring intensive therapeutic approaches.
- Allogeneic stem cell transplantation as postremission therapy may improve outcomes for patients with RS.
- Ongoing clinical trials exploring novel combination regimens, such as oxaliplatin, fludarabine, cytarabine, and rituximab, aim to improve cure rates for RS.